[1] 中华医学会肝病学分会,中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015年). 临床肝胆病杂志, 2015,31(12):1980-1988. [2] Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol, 2020, 17(2):93-110. [3] Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol, 2018,16(8):1342-1350. [4] Shin S, Moh IH, Woo YS, et al. Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis. World J Gastroenterol, 2017,23(39):7191-7197. [5] Wang L, Gershwin ME, Wang F. Primary biliary cholangitis in China. Curr Opin Gastroenterol, 2016:35(3):195-203. [6] Smyk DS, Rigopoulou EI, Pares A, et al. Familial primary biliary cirrhosis: like mother, like daughter? Acta Gastroenterol Belg, 2012,75(2):203-209. [7] Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology, 2003,125(5):1476-1479. [8] Thomsen H, Li X, Sundquist K, et al. Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases. PloS One, 2020,15(10):e240794. [9] Fan X, Wang T, Shen Y, et al. Underestimated male prevalence of primary biliary cholangitis in China: results of a 16-yr cohort study involving 769 patients. Sci Rep, 2017,7(1):6560. [10] Lazaridis KN, Juran BD, Boe GM, et al. Increased prevalence of antimitochondrial antibodies in first‐degree relatives of patients with primary biliary cirrhosis. Hepatology, 2007,46(3):785-792. [11] Lleo A, Oertelt-Prigione S, Bianchi I, et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun, 2013,41:87-91. [12] Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology, 2004,127(2):485-492. [13] Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet, 2015,386(10003):1565-1575. [14] 郝建宏,郝海燕,胡忆玲.94例原发性胆汁性肝硬化临床特征分析.实用肝脏病杂志,2016,19(3):352-353. [15] Lleo A, Jepsen P, Morenghi E, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep, 2016,6(1):25906. [16] Lazaridis KN, Juran BD, Boe GM, et al. Increased prevalence of antimitochondrial antibodies in first‐degree relatives of patients with primary biliary cirrhosis. Hepatology, 2007,46(3):785-792. [17] 袁洲, 贾桂, 韩英. 原发性胆汁性胆管炎熊去氧胆酸治疗应答不佳危险因素的研究进展. 中华肝脏病杂志, 2019,27(1):73-76. [18] 张鑫赫,田昊宇,李异玲.原发性胆汁性胆管炎治疗现状.实用肝脏病杂志,2021,24(3):453-456. [19] Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology, 2005,128(2):297-303. [20] Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. J Hepatol, 2003,39(1):112-114. |